四川港通医疗设备集团股份有限公司 2025年限制性股票激励计划自查表 | | 公司简称：港通医疗 股票代码：301515 | 独立财务顾问：无 | | | --- | --- | --- | --- | | 序号 | 事项 | 是否存在该 事项（是/否 | 备注 | | | | /不适用） | | | | 上市公司合规性要求 | | | | 1 | 最近一个会计年度财务会计报告是否被注册会计师出具否定 | 否 | | | | 意见或者无法表示意见的审计报告 | | | | 2 | 最近一个会计年度财务报告内部控制被注册会计师出具否定 | 否 | | | | 意见或者无法表示意见的审计报告 | | | | 3 | 上市后最近36个月内出现过未按法律法规、公司章程、公开承 | 否 | | | | 诺进行利润分配的情形 | | | | 4 | 是否存在其他不适宜实施股权激励的情形 | 否 | | | 5 | 是否已经建立绩效考核体系和考核办法 | 是 | | | 6 | 是否为激励对象提供贷款以及其他任何形式的财务资助 | 否 | | | | 激励对象合规性要求 | | | | | 是否包括单独或者合计持有上市公司 ...

上海君澜律师事务所 关于 四川港通医疗设备集团股份有限公司 2025 年限制性股票激励计划（草案） 之 法律意见书 二〇二五年七月 上海君澜律师事务所 法律意见书 释 义 在本法律意见书中，除非文意另有所指，下列词语具有以下含义： | 公司/港通医疗 | 指 | 四川港通医疗设备集团股份有限公司 | | --- | --- | --- | | 《激励计划（草案）》 | 指 | 《四川港通医疗设备集团股份有限公司 年限制 2025 | | | | 性股票激励计划（草案）》 | | 本次激励计划 | 指 | 四川港通医疗设备集团股份有限公司拟根据《四川港 | | | | 通医疗设备集团股份有限公司 2025 年限制性股票激 | | | | 励计划（草案）》实施的股权激励 | | 《考核办法》 | 指 | 《四川港通医疗设备集团股份有限公司 年限制 2025 | | | | 性股票激励计划实施考核管理办法》 | | 激励对象 | 指 | 按照本次激励计划之规定，获得限制性股票的在公司 | | | | （含控股子公司）任职的高级管理人员、中层管理人 | | | | 员、基层管理人员及核心技术（业务）骨干 | | 限制 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-037 四川港通医疗设备集团股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第五届董事会第 二次会议于 2025 年 7 月 1 日在公司会议室以现场结合通讯的方式召开。本次会 议通知于 2025 年 6 月 27 日以通讯方式发出，会议应出席董事 9 人，实际出席董 事 9 人（其中：刘煜强先生、魏勇先生、陈叙先生以通讯表决方式出席会议）。 会议由董事长陈永先生召集并主持，财务总监张秋先生列席了本次会议。本次会 议的召集、召开符合《公司法》和《公司章程》的有关规定，会议合法有效。 一、董事会会议审议情况 经过各位董事认真审议，本次会议形成如下决议： （一）审议通过《关于〈四川港通医疗设备集团股份有限公司 2025 年限制 性股票激励计划（草案）〉及其摘要的议案》 为进一步促进公司建立、健全有效的激励约束机制，充分调动公司员工的积 极性，有效地将股东利益、公司利益和员工个人利益紧密结合，使各方共同关注 ...

证券代码：301515 证券简称：港通医疗 公告编号：2025-038 四川港通医疗设备集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东会届次：2025年第一次临时股东会 2．股东会的召集人：公司董事会 7．出席对象： （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 于股权登记日下午收市时在中国证券登记结算有限责任公司深圳分公司登记 在册的公司全体已发行有表决权股份的股东均有权出席本次股东会，并可以以书 面形式委托代理人出席会议和参加表决，该股东代理人不必是本公司的股东。 （2）公司董事、高级管理人员； 3．会议召开的合法、合规性：经公司第五届董事会第二次会议审议通过《关 于提议召开公司2025年第一次临时股东会的议案》，本次股东会的召集、召开程序 符合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所相关业务规 则和《公司章程》的规定。 4．会议召开的日期、时间： （1）现场会议时间：2025年7月18日（星期五）下午2点 （2）网络投票时间：通 ...

Core Viewpoint - The financial performance of 港通医疗 (301515.SZ) has significantly declined in both 2024 and the first quarter of 2025, with substantial drops in revenue and net profit compared to previous periods [1][2][3]. Financial Performance Summary - For Q1 2025, the company reported revenue of 24.29 million yuan, a decrease of 68.09% year-on-year [2] - The net profit attributable to shareholders was 1.58 million yuan, down 85.25% year-on-year [2] - The net profit after excluding non-recurring items was 1.41 million yuan, a decline of 86.46% year-on-year [2] - The net cash flow from operating activities was -15.09 million yuan, compared to 37.50 million yuan in the same period last year [2] Annual Financial Results - In 2024, the company achieved revenue of 754.06 million yuan, a decrease of 10.49% compared to 2023 [3] - The net profit attributable to shareholders was 14.42 million yuan, down 82.64% year-on-year [3] - The net profit after excluding non-recurring items was 5.01 million yuan, a decline of 91.74% year-on-year [3] - The net cash flow from operating activities improved to -10.94 million yuan from -114.32 million yuan in the previous year [3] Previous Year Comparison - In 2023, the company reported revenue of 842.44 million yuan, an increase of 9.62% from 2022 [4] - The net profit attributable to shareholders was 83.10 million yuan, up 12.40% year-on-year [4] - The net profit after excluding non-recurring items was 60.63 million yuan, a decrease of 13.93% year-on-year [4] - The net cash flow from operating activities was -11.43 million yuan, compared to 49.94 million yuan in 2022 [4] IPO and Fundraising - 港通医疗 was listed on the Shenzhen Stock Exchange's ChiNext on July 25, 2023, with an issuance of 25 million shares at a price of 31.16 yuan per share [6] - The total funds raised amounted to 779 million yuan, with a net amount of 689.99 million yuan, exceeding the initial plan by 29.996 million yuan [6] - The funds are intended for the construction of a smart medical equipment production base, upgrading the R&D technology center, and supplementing working capital [6]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Kangtong Medical, which has a high PE ratio compared to its industry peers [1][2] - As of June 16, Kangtong Medical's stock closed at 19.8 yuan, with a rolling PE ratio of 374.05, significantly higher than the industry average of 49.56 [1][2] - The company has a total market capitalization of 1.98 billion yuan, ranking 120th in the medical device industry based on PE ratio [1][2] Group 2 - Kangtong Medical's main business includes the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as clean medical equipment [1] - The company has received multiple accolades, including being recognized as a "National Specialized and Innovative Small Giant Enterprise" and a "National High-tech Enterprise" [1] - The latest financial report for Q1 2025 shows a revenue of 2,428.67 million yuan, a year-on-year decrease of 68.09%, and a net profit of 157.90 million yuan, down 85.25% [1]

Group 1 - The company held its first meeting of the fifth board of directors on June 11, 2025, with all nine directors present, and the meeting was deemed legal and effective [1][2]. - The board elected Chen Yong as the chairman of the fifth board of directors for a term of three years starting from the approval date [1][2]. - The board approved the election of committee members, including Chen Yong as the head of the strategy committee and Zhao Chen as the head of the audit committee, with all votes in favor [2]. Group 2 - The board appointed Chen Yong as the general manager, Chen Xinggen as the board secretary and deputy general manager, and several others as vice general managers and financial director, with unanimous approval [2][3]. - Chen Lijia was appointed as the securities affairs representative for a term of three years, also receiving unanimous support [3]. - The board proposed to provide a guarantee of up to 8 million yuan for the financing needs of its wholly-owned subsidiary, Sichuan Meidifa Medical Equipment Co., Ltd., with the guarantee valid for 12 months [3].

证券代码：301515 证券简称：港通医疗 公告编号：2025-032 四川港通医疗设备集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开情况 董事会； 会议室； （1）通过深圳证券交易所交易系统进行网络投票的具体时间为2025年6月11 日的交易时间，即9:15-9:25，9:30—11:30和13:00—15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的开始时间为2025 年6月11日上午9:15，结束时间为2025年6月11日下午15:00。 法律法规、部门规章、规范性文件和《公司章程》的规定。 （二）会议出席情况 出席本次股东会的股东和股东授权委托代表共66人，代表股份37,690,800股， 占公司有表决权股份总数的39.2436%（截至本次股东会股权登记日，公司回购专 用证券账户回购的股份数为3,956,856股，不计入公司有表决权股份总数，公司 有表决权股份总数为96,043,144股）。其中： 出席现场会议（含视频方式）的股东和股东授权委托代表共13人，代表股份 ...

北京金杜（成都）律师事务所 届董事会第二十次会议决议公告》； 息披露媒体的《第四届监事会第十九次会议决议公告》； 息披露媒体的《四川港通医疗设备集团股份有限公司关于召开 2024 年年度股东会 的通知》（以下简称《股东会通知》）； 关于四川港通医疗设备集团股份有限公司 致：四川港通医疗设备集团股份有限公司 北京金杜（成都）律师事务所（以下简称本所）接受四川港通医疗设备集团股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》） 、《中华人民共和国公司法》 （以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以 下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门 特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和现行 有效的公司章程有关规定，指派律师出席公司于 2025 年 6 月 11 日召开的 2024 年年度股东会（以下简称本次股东会），并对本次股东会的相关事项出具本法律意 见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 限公司章程》（以下 ...

Group 1 - The company completed the election of the fifth board of directors and appointed senior management and securities affairs representative [1][2] - The fifth board of directors consists of 9 members, with a term of three years starting from the approval date of the annual shareholders' meeting [1][2] - The board includes independent directors and employee representatives, ensuring compliance with regulations regarding board composition [2] Group 2 - The senior management team includes General Manager Chen Yong, Secretary of the Board Chen Xinggen, and Chief Financial Officer Zhang Qiu [3] - The securities affairs representative is Chen Lijia, who holds relevant qualifications [3][18] - The appointed senior management and securities affairs representative will serve a term of three years [3] Group 3 - The fourth supervisory board's term has expired, and three supervisors have stepped down but will continue to work in the company [4][5] - The departing supervisors include Shi Wencong, Li Lanying, and Chen Liangping, with their shareholdings disclosed [5]